# US 6,720,009 B2 · Matrix protein compositions for treating infection > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 6,720,009 B2 - Document ID: US6720009B2 - Status: Granted - Kind: B2 - Application number: 10/156,300 - Filed: 2002-05-28 - Published: 2003-04-03 - Granted: 2004-04-13 - Earliest claimed: 1998-02-27 - Assignees: Biora BioEx AB - Inventors: Stina Gestrelius; Lars Hammarström; Petter Lyngstadaas; Christer Andersson; Ivan Slaby; Tomas Hammargren - Web page: https://patentgrep.com/patent/US6720009B2 ## CPC - A61K 8/19: containing inorganic ingredients - A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof - A61K 8/981: {of mammals or bird} - A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] - A61L 15/32: Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin {(A61L15/225 takes precedence)} - A61L 24/108: {Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106} - A61L 26/0047: {Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042} - A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24} - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/04: Antibacterial agents - A61Q 11/00: Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses - A61Q 17/005: {Antimicrobial preparations} - A61Q 19/00: Preparations for care of the skin - Y10S 977/906: Drug delivery - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS - Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS ## Abstract Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection or inflammation. ## Claims ### Claim 1 A method of treating an infection, the method comprising administering to a mammal in need thereof a prophylactically or therapeutically effective amount of an active enamel substance. ### Claim 2 (depends on 1) The method according to claim 1, wherein the active enamel substance is selected from the group consisting of enamelins, amelogenins, non-amelogenins, proline-rich non-ameiogenins, amelins, tuftelins, derivatives thereof, and mixtures thereof. ### Claim 3 (depends on 2) The method according to claim 2, wherein said amelin is ameloblastin or sheathlin. ### Claim 4 (depends on 1) The method according to claim 1, wherein the active enamel substance has a molecular weight of at most about 60 kd to at most about 120 kDa, as determined by SDS Page electrophoresis. ### Claim 5 (depends on 1) The method according to claim 1, wherein the infection is a bacterial infection of the skin or of a mucosal surface. ### Claim 6 (depends on 1) The method according to claim 1, wherein the bacterial infection is an infection of the oral cavity. ### Claim 7 (depends on 6) The method according to claim 6, wherein the infection is caused by bacteria causing caries, bacteria causing periodontal disease, bacteria causing alveolitis, and bacteria causing periapical lesions. ### Claim 8 (depends on 7) The method according to claim 7, wherein the bacteria causing caries is Streptococcus mutans. ### Claim 9 (depends on 7) The method according to claim 7, wherein the bacteria causing periodontal disease is selected from the group consisting of Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Peptostreptoccus micros, a Campylobacter and B. forsythus. ### Claim 10 (depends on 9) The method according to claim 9, wherein the Campylobactor is a Fusobacteria or Staphylocci. ### Claim 11 (depends on 7) The method according to claim 7, wherein the bacteria causing alveolitis is selected from the group consisting of Staphylococcus, Actinomyces, and Bacillus. ### Claim 12 (depends on 7) The method according to claim 7, wherein the bacteria causing periapical lesions is Spirochetes. ### Claim 13 (depends on 1) The method according to claim 1, comprising administering the active enamel substance to skin, to a mucosa, to a non-oral tissue, to a surgical incision, or to an internal wound. ### Claim 14 (depends on 13) The method according to claim 13, wherein the mucosa is selected from oral, buccal, nasal, aural, rectal and vaginal mucosa. ### Claim 15 (depends on 1) The method according to claim 1, wherein the active enamel substance is provided on or in a bandage, dressing, drench, patch, sheet, plaster, pad, soap, stick, sponge, transdermal delivery system, or denture. ### Claim 16 (depends on 1) The method according to claim 1, wherein the active enamel substance is provided in a capsule, tablet, pill, pellet, inhalation device, delivery device, spray, aerosol, shampoo, or enema. ### Claim 17 (depends on 1) The method according to claim 1, wherein the active enamel substance is provided as an implant or a coating of an implant. ### Claim 18 (depends on 1) The method according to claim 1, wherein the active enamel substance comprises a peptide comprising at least one sequence element selected from the group consisting of Asp-Gly-Glu-Ala, Val-Thr-Lys-Gly, Glu-Lys-Gly-Glu, and Asp-Lys-Gly-Glu. ### Claim 19 (depends on 18) The method according to claim 18, wherein the active enamel substance further comprises an amino acid sequence comprising a consecutive string of 20 amino acids at least 80% identical with a string of amino acids of the same length obtained from a polypeptide comprising SEQ ID NO. 1, amino acids 1 to 103 of SEQ ID NO. 1, or amino acids 6-324 of SEQ ID NO. 2.